CFTR modulators modify exhaled breath of children with cystic fibrosis within a week.
Emmanuelle Bardin(Centre National de la Recherche Scientifique), Isabelle Sermet‐Gaudelus(Hôpital Necker-Enfants Malades), F. Chedevergne(Hôpital Necker-Enfants Malades), Nicolas Hunzinger(Inserm), Bingqing Zhou(Inserm), Laurence Le Clainche Viala(Assistance Publique – Hôpitaux de Paris), Elodie Lamy(Inserm), Stanislas Grassin‐Delyle(Inserm), N. Rémus(Hôpital Intercommunal de Créteil), Philippe Devillier(Université Paris-Saclay)
Cited by 1
Related Papers
<i>Pseudomonas aeruginosa</i>infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
|Expert Review of Respiratory Medicine|2016|170
<i>Mycobacterium abscessus</i>and Children with Cystic Fibrosis
|Emerging infectious diseases|2003|159
Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
|FEMS Microbiology Letters|2017|107
Modulators of CFTR. Updates on clinical development and future directions
|European Journal of Medicinal Chemistry|2021|67